Experience in preparing obese patients for infertility treatment


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Objective. To study whether Reduxin Forte can be used in obese patients planning IVF. Subjects and methods. Thirty women with grade 1 obesity were examined and treated. Along with physical exercises and diet, Reduxin Forte (sibutramine 10-15 mg/day + metformin 850 mg/day) was used in the patients for 3 months. Anthropometric and carbohydrate metabolic parameters and the oxidative stress marker 8-0H-deoxyguanosine (8-0HdG) were estimated before and after treatment. Results. Prior to and following treatment, there were reductions in weight by 10.8% (90.597+5.79 vs. 80.773+5.58 kg; p = 0.017), BMI (33.324+1.53 vs. 29.719+1.55; p = 0.002), waist (96.733+3.92 vs. 89.133+3.91 cm; p = 0.008) and hip (114.067+4.40 vs. 107.733+3.54 cm; p = 0.028) circumferences. It should be emphasized that there were also decreases in insulin levels (15.271+2.67vs. 10.049+1.72pU/ml;p = 0.002), H0MA index (3.673+0.67 vs. 2.28+0.41; p < 0.001), and the levels of the oxidative stress marker 8-0HdG (0.361+0.082 vs. 0.240+0.029 ng/ml; p = 0.007). Conclusion. Three-month use of Reduxin Forte in patients with grade I obesity, who planned IVF, improved anthropometric parameters, normalized carbohydrate metabolism, and decreased 8-0HdG levels. Pregnancy after VF and in a natural cycle occurred in 8/18 (44.4%) and 8/26 (30.7%) of women, respectively.

Негізгі сөздер

Толық мәтін

Рұқсат жабық

Авторлар туралы

Tamara Zhuk

Altai State Medical University, Ministry of Health of the Russian Federation; Siberian Institute of Human Reproduction and Genetics

Svetlana Yavorskaya

Altai State Medical University, Ministry of Health of the Russian Federation

Vyacheslav Vostrikov

Siberian Institute of Human Reproduction and Genetics

Email: wkoctar@mail.ru

Vladimir Nagaitsev

Siberian Institute of Human Reproduction and Genetics

Email: ivfaltai@mail.ru

Alexey Kotov

Siberian Institute of Human Reproduction and Genetics

Email: 501077@bk.ru

Әдебиет тізімі

  1. Correa A., Marcinkevage J. Prepregnancy obesity and the risk of birth defects: an update. Nutr Rev. 2013; 71(Suppl. 1): 68-77. doi: 10.1111/nure.12058.
  2. Dolin C.D., Kominiarek M.A. Pregnancy in women with obesity. Obstet Gynecol Clin North Am. 2018; 45: 217-32. http://dx.doi.org/10.1016/j.ogc.2018.01.005
  3. Sneed M.L., Uhler M.L., Grotjan H.E., et al. Body mass index: impact on IVF success appears age-related. Hum Reprod. 2008; 23(8): 1835-9. https://doi. org/10.1093/humrep/den188
  4. Poston L., Caleyachetty R., Cnattingius S., Corvalan C., Uauy R., Herring S., et al. Preconceptional and maternal obesity: epidemiology and health consequences. Lancet Diabetes Endocrinol.2016; 4(12): 1025-1036. doi: 10.1016/S2213-8587(16)30217-0.
  5. Rasmussen S.A., Chu S.Y., Kim S.Y., Schmid C.H., Lau J. Maternal obesity and risk of neural tube defects: a metaanalysis. Am. J. Obstet. Gynecol. 2008; 198(6): 611-9. doi: 10.1016/j.ajog.2008.04.021.
  6. Poston L., Caleyachetty R., Cnattingius S., Corvalan C., Uauy R., Herring S., et al. Preconceptional and maternal obesity: epidemiology and health consequences. Lancet Diabetes Endocrinol. 2018; 4: 1025-36. doi: 10.1016/ S2213-8587(16)30217-0.
  7. Most J., Marlatt K. L., Altazan A. D., Redman L. M. Advances in assessing body composition during pregnancy. Eur J. Clin Nutr. 2018; 72: 645-56. doi: 10.1038/s41430-018-0152-8.
  8. Bozkurt L., Gobl C. S., Hormayer A.T., Luger A., Pacini G., Kautzky-Willer A. The impact of preconceptional obesity on trajectories of maternal lipids during gestation. Sci. Rep.2016; 6: 29971. doi: 10.1038/srep29971.
  9. Burton G.J., Jauniaux E. Oxidative stress. Best Practice & Research Clinical Obstetrics & Gynaecology. 2011; 25(3): 287-99. doi: 10.1016/j. bpobgyn.2010.10.016
  10. Alcala M., Sanchez-Vera I., Sevillano J., Herrero L., Serra D., Ramos M.P., et al. Vitamin E. reduces adipose tissue fibrosis, inflammation, and oxidative stress and improves metabolic profile in obesity. Obesity. 2015; 23(8): 1598-1606. doi: 10.1002/oby.21135
  11. Agarwal A., Aziz N., Rizk B. Studies on Women’s Health. HumanaPress, NewYork; 2013; 33-60. doi:https://doi.org/10.1007/978-1-62703-041-0.
  12. Matsuda M., Shimomura I. Increased oxidative stress in obesity: implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer. Obes. Res. Clin. Pract. 2013; 7: 330-341. doi: 10.1016/j.orcp.2013.05.004
  13. Agarwal A., Aponte-Mellado A., Premkumar B.J., et al. The effects of oxidative stress on female reproduction: a review. Reprod Biol Endocrinol. 2012; 10(1): 49. doi: 10.1186/1477-7827-10-49.
  14. Savini I., Catani M.V., Evangelista D., Gasperi V., Avigliano L. Obesity-associated oxidative stress: strategies finalized to improve redox state. Int. J. Mol. Sci. 2013; 14: 10497-538. doi: 10.3390/ijms140510497.
  15. Alcala M., Calderon-Dominguez M., Serra D., Herrero L., Ramos M.P., Viana M. Short-term vitamin E. treatment impairs reactive oxygen species signaling required for adipose tissue expansion, resulting in fatty liver and insulin resistance in obese mice. PLoS One 2017; 23-56. https://doi.org/10.1371/ journal.pone.0186579
  16. Wu F., Tian F.J., Lin Y. Oxidative stress in placenta: health and diseases. Biomed. Res. Int. 2015; 293271. https://doi.org/10.1155/2015/293271
  17. Malti N., Merzouk H., Merzouk S.A., Loukidi B., Karaouzene N., Malti A., et al. Oxidative stress and maternal obesity: feto-placental unit interaction. Placenta 2014; 35: 411-6. doi: 10.1016/j.placenta.2014.03.010.
  18. ck C.Y., Kim E.H., Choi D.J., Lee H.J., Hahm K.B., Chung M.H. 8-Hydroxydeoxyguanosine: not mere biomarker for oxidative stress, but remedy for oxidative stress-implicatedgastrointestinal diseases. World J. Gastroenterol. 2012; 18(4): 302-8. doi: 10.3748/wjg.v18.i4.302.
  19. Nguyen D.M., El-Serag H.B. The epidemiology of obesity. Gastroenterol Clin North Am. 2010; 39(1):1-7. https://doi.org/10.1016/ j.gtc.2009.12.014
  20. Дедов И.И., Романцова Т.И., Шестакова М.В. Рациональный подход к терапии пациентов с СД2 и ожирением: итоги всероссийской наблюдательной программы «АВРОРА» Ожирение и метаболизм. 2018; 15(4): 48-58.
  21. Востриков В.В., Маркова Е.А., Кузнецова Т.А., Елизарьев А.Ю. Этиология и патогенез синдрома гиперстимуляции яичников. Современные аспекты диагностики, лечения и профилактики. Барнаул: Алтайский медицинский университет, 2016. 60 с.
  22. Иванова А.Р. Меди ко-психологические особенности женщин во время лечения бесплодия: автореф. дис. канд. мед. наук. М., 2010.
  23. Жук Т.В., Яворская С.Д., Востриков В.В., Немцева Г.В. Прогноз эффективности экстракорпорального оплодотворения у пациенток с трубно-перитонеальным бесплодием и ожирением. Российский вестник акушера-гинеколога. 2019; 19(1): 66-9. doi: 10.17116/rosakush20191901166

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2020

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>